No Data
No Data
Press Release: Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Nautilus Biotechnology Insider Ups Holding During Year
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Insider Traders Lose US$20k As Nautilus Biotechnology Drops
Morgan Stanley Maintains Nautilus Biotechnology(NAUT.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley analyst Yuko Oku maintains $Nautilus Biotechnology(NAUT.US)$ with a hold rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 0.0%
TD Cowen Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating
TD Cowen analyst Daniel Brennan maintains $Nautilus Biotechnology(NAUT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 54.3% and a total average return of 9.6%